 |
|
Effect of Warfarin on Activated Partial Thromboplastin Time in Patients Receiving Heparin
Clive Kearon, MB, PhD;
Marilyn Johnston, ART;
Karen Moffat, ART;
Joanne McGinnis, RN;
Jeffrey S. Ginsberg, MD
Arch Intern Med. 1998;158:1140-1143.
Background The activated partial thromboplastin time (APTT) is used to adjust heparin sodium dosage. However, warfarin sodium is often administered concomitantly with heparin and may also affect the APTT and, therefore, heparin dose. We performed a prospective cohort study to quantify the effect of warfarin on the APTT in patients who are being treated with heparin.
Methods Serial assays of APTT, international normalized ratio, heparin levels, and functional levels of prothrombin (factor II) and factors VII and X were performed in 24 patients with acute venous thromboembolism who were treated with concomitant continuous intravenous heparin and warfarin. The effects of warfarin, as expressed by international normalized ratio and coagulation factor levels, on APTT were determined.
Results Warfarin markedly affected APTT; for each increase of 1.0 in the international normalized ratio, the APTT increased 16 seconds (95% confidence interval, 10-22 seconds). The effects of warfarin and heparin on APTT were additive. Consequently, warfarin markedly altered the relationship between APTT and heparin levels; of the 29 blood samples with supratherapeutic APTT, 13 had a therapeutic heparin level and 10 had a subtherapeutic heparin level.
Conclusions In patients receiving concomitant heparin and warfarin therapy, APTT reflects the combined effects of both drugs. Because of the marked effect of warfarin on the APTT, decreasing heparin dose in response to a high APTT frequently results in subtherapeutic heparin levels.
From the Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
Kearon et al.
JAMA 2006;296:935-942.
ABSTRACT
| FULL TEXT
Kubiak et al.
The Annals of Pharmacotherapy 2005;39:1956-1957.
FULL TEXT
Comment: extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer
Spinler and Dager
The Annals of Pharmacotherapy 2005;39:1955-1956.
FULL TEXT
The Management of Venous Thromboembolic Disease in Older Adults
Rich
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M34-41.
ABSTRACT
| FULL TEXT
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers et al.
Chest 2001;119:176S-193S.
FULL TEXT
Pulmonary Embolism
Schrijvers et al.
NEJM 1998;339:1555-1557.
FULL TEXT
|
